Format
Sort by
Items per page

Send to

Choose Destination

Best matches for trastuzumab:

ABP 980: A Trastuzumab Biosimilar. Dhillon S et al. BioDrugs. (2018)

Trastuzumab cardiotoxicity: from clinical trials to experimental studies. Nemeth BT et al. Br J Pharmacol. (2017)

The Ecstacy of Gold: Patent Expirations for Trastuzumab, Bevacizumab, Rituximab, and Cetuximab. Serna-Gallegos TR et al. Recent Pat Biotechnol. (2018)

Search results

Items: 1 to 20 of 10899

1.

The impact of hormone receptor status on survival and recurrence of HER2-positive breast cancers in standard adjuvant setting: A retrospective study in Tehran, Iran.

Sadeghi M, Najafi S, Shajari MR, Abasvandi F, Mohebi K.

J Pak Med Assoc. 2020 Jan;70(1):11-16. doi: 10.5455/JPMA.290165.

2.

A randomized, 3-arm, neoadjuvant, phase 2 study comparing docetaxel + carboplatin + trastuzumab + pertuzumab (TCbHP), TCbHP followed by trastuzumab emtansine and pertuzumab (T-DM1+P), and T-DM1+P in HER2-positive primary breast cancer.

Masuda N, Ohtani S, Takano T, Inoue K, Suzuki E, Nakamura R, Bando H, Ito Y, Ishida K, Yamanaka T, Kuroi K, Yasojima H, Kasai H, Takasuka T, Sakurai T, Kataoka TR, Morita S, Ohno S, Toi M.

Breast Cancer Res Treat. 2020 Jan 17. doi: 10.1007/s10549-020-05524-6. [Epub ahead of print]

PMID:
31953696
3.

The lipid composition affects Trastuzumab adsorption at monolayers at the air-water interface.

Sakai A, de Sousa Mesquista AP, Nader HB, Lopes CC, Nakanishi W, Ariga K, Caseli L.

Chem Phys Lipids. 2020 Jan 14:104875. doi: 10.1016/j.chemphyslip.2020.104875. [Epub ahead of print]

PMID:
31952936
4.

Takotsubo cardiomyopathy caused by infusion reaction to trastuzumab.

Matsumoto T, Oda T, Yoshida Y, Kimura S, Himei H, Tsuduki T, Takagi S, Takatani M, Morishita H.

Int Cancer Conf J. 2019 Dec 6;9(1):28-31. doi: 10.1007/s13691-019-00396-0. eCollection 2020 Jan.

PMID:
31950014
5.

Sinusoidal obstruction syndrome post-treatment with trastuzumab emtansine (T-DM1) in advanced breast cancer.

Fujii Y, Doi M, Tsukiyama N, Hattori Y, Ohya K, Shiroma N, Morio K, Morioka T, Aikata H, Shinozaki K, Chayama K.

Int Cancer Conf J. 2019 Oct 24;9(1):18-23. doi: 10.1007/s13691-019-00392-4. eCollection 2020 Jan.

PMID:
31950012
6.

Bioinformatics Analysis of Potential Key Genes in Trastuzumab-Resistant Gastric Cancer.

Yang G, Jian L, Lin X, Zhu A, Wen G.

Dis Markers. 2019 Dec 17;2019:1372571. doi: 10.1155/2019/1372571. eCollection 2019.

7.

Recent advances and optimal management of human epidermal growth factor receptor-2-positive early-stage breast cancer.

Batoo S, Bayraktar S, Al-Hattab E, Basu S, Okuno S, Glück S.

J Carcinog. 2019 Dec 31;18:5. doi: 10.4103/jcar.JCar_14_19. eCollection 2019. Review.

PMID:
31949426
8.
9.

Detection of HER2+ Breast Cancer Cells using Bioinspired DNA-Based Signal Amplification.

Rafiee SD, Kocabey S, Mayer M, List J, Rüegg C.

ChemMedChem. 2020 Jan 13. doi: 10.1002/cmdc.201900697. [Epub ahead of print]

PMID:
31943804
10.

Impact of BMI on HER2+ metastatic breast cancer patients treated with pertuzumab and/or trastuzumab emtansine. Real-world evidence.

Eriseld K, Laura P, Giacomo B, Domenico S, Silvia C, Claudio B, Ramy K, Giuseppe S, Paolo M, Andrea B, Daniele M, Teresa G, Clara N, Antonino G, Nicola T, Silverio T, Giuseppe T, Daniele S, Aandrea M, Lucia M, Aangela V, Emanuela M, Alain G, Valentina M, Enrico C, Loretta D, Alessandra C, Marina C, Luca M, Agnese F, Angelo Fedele S, Domenico C, Luisa C, Emilio B, Nicla V, Carlo G, Pia DS, Rossana M, Enzo V, Ida P, Francesco G, Vito L, Elisa L, Corrado F, Mario R, Vincenzo A, Giuseppina R, Antonio R, Maria Rosaria V, Rossana B, Mirco P, Katia C, Claudio Z, Ornella G, Editta B, Lorenzo L, Icro M, Pietro DM, Daniele G, Ruggero M, Emanuela R, Gennaro C, Alice V, Isabella S, Marco M, Maddalena B, Antonio G, Patrizia V.

J Cell Physiol. 2020 Jan 15. doi: 10.1002/jcp.29445. [Epub ahead of print]

PMID:
31943171
11.

An Agent-Based Systems Pharmacology Model of the Antibody-Drug Conjugate Kadcyla to Predict Efficacy of Different Dosing Regimens.

Menezes B, Cilliers C, Wessler T, Thurber GM, Linderman JJ.

AAPS J. 2020 Jan 15;22(2):29. doi: 10.1208/s12248-019-0391-1.

PMID:
31942650
12.

Histone deacetylase inhibitors valproic acid and vorinostat enhance trastuzumab-mediated antibody-dependent cell-mediated phagocytosis.

Laengle J, Kabiljo J, Hunter L, Homola J, Prodinger S, Egger G, Bergmann M.

J Immunother Cancer. 2020 Jan;8(1). pii: e000195. doi: 10.1136/jitc-2019-000195. Epub 2020 Jan 2.

13.

Long-term Cardiopulmonary Consequences of Treatment-Induced Cardiotoxicity in Survivors of ERBB2-Positive Breast Cancer.

Yu AF, Flynn JR, Moskowitz CS, Scott JM, Oeffinger KC, Dang CT, Liu JE, Jones LW, Steingart RM.

JAMA Cardiol. 2020 Jan 15. doi: 10.1001/jamacardio.2019.5586. [Epub ahead of print]

PMID:
31939997
14.

Antibody Coadministration as a Strategy to Overcome Binding-Site Barrier for ADCs: a Quantitative Investigation.

Singh AP, Guo L, Verma A, Wong GG, Thurber GM, Shah DK.

AAPS J. 2020 Jan 14;22(2):28. doi: 10.1208/s12248-019-0387-x.

PMID:
31938899
15.

Effect of Trastuzumab among HER2-Positive Breast Cancer Patients that Achieved Pathologic Complete Response after Neoadjuvant Chemotherapy.

Wang X, He Y, Fan Z, Wang T, Xie Y, Li J, Ouyang T.

Breast Care (Basel). 2019 Dec;14(6):388-393. doi: 10.1159/000495186. Epub 2019 Feb 5.

PMID:
31933585
16.

A comparison of DFO and DFO* conjugated to trastuzumab-DM1 for complexing 89Zr - In vitro stability and in vivo microPET/CT imaging studies in NOD/SCID mice with HER2-positive SK-OV-3 human ovarian cancer xenografts.

Cho H, Al-Saden N, Lam H, Möbus J, Reilly RM, Winnik MA.

Nucl Med Biol. 2019 Dec 30;84-85:11-19. doi: 10.1016/j.nucmedbio.2019.12.009. [Epub ahead of print]

PMID:
31931305
17.

Comparison of Utilization Trends between Biosimilars and Generics: Lessons from the Nationwide Claims Data in South Korea.

Lee HJ, Han E, Kim H.

Appl Health Econ Health Policy. 2020 Jan 13. doi: 10.1007/s40258-019-00547-7. [Epub ahead of print]

PMID:
31930450
18.

Cardiac Safety of the Trastuzumab Biosimilar ABP 980 in Women with HER2-Positive Early Breast Cancer in the Randomized, Double-Blind, Active-Controlled LILAC Study.

Kolberg HC, Colleoni M, Demetriou GS, Santi P, Tesch H, Fujiwara Y, Tomasevic Z, Hanes V.

Drug Saf. 2020 Jan 11. doi: 10.1007/s40264-019-00886-3. [Epub ahead of print]

PMID:
31927716
19.

Increased assessment of HER2 in metastatic gastroesophageal cancer patients: a nationwide population-based cohort study.

Dijksterhuis WPM, Verhoeven RHA, Meijer SL, Slingerland M, Haj Mohammad N, de Vos-Geelen J, Beerepoot LV, van Voorthuizen T, Creemers GJ, van Oijen MGH, van Laarhoven HWM.

Gastric Cancer. 2020 Jan 11. doi: 10.1007/s10120-020-01039-7. [Epub ahead of print]

PMID:
31927675
20.

A case of stage IV gastric cancer with para-aortic lymph node metastasis showing pathological complete response after neoadjuvant chemotherapy.

Katsura Y, Okabayashi T, Matsumoto M, Ozaki K, Shibuya Y.

Surg Case Rep. 2020 Jan 10;6(1):14. doi: 10.1186/s40792-020-0788-1.

PMID:
31925618

Supplemental Content

Loading ...
Support Center